Fibrocell Science Inc (NASDAQ:FCSC) traded up 5.8% during trading on Monday . The stock traded as high as $0.75 and last traded at $0.73. 1,253,400 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 1,702,550 shares. The stock had previously closed at $0.69.

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.70 price target on shares of Fibrocell Science in a report on Friday, September 15th. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.21.

The stock has a market cap of $15.27, a price-to-earnings ratio of -0.38 and a beta of 0.40.

In other Fibrocell Science news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the stock in a transaction on Monday, December 11th. The shares were bought at an average cost of $0.77 per share, with a total value of $2,100,000.21. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC lifted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,259 shares of the company’s stock after acquiring an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned 0.33% of Fibrocell Science worth $194,000 as of its most recent SEC filing. Institutional investors own 31.64% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Fibrocell Science (FCSC) Trading 5.8% Higher” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with Analyst Ratings Network's FREE daily email newsletter.